Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs

SEATTLE–(BUSINESS WIRE)–Pluristyx, a leading provider of tools, technologies, and services for the development of cellular therapies, is pleased to announce a license agreement with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale. Humacyte has licensed Pluristyx’s clinical-grade PluriBank™ induced Pluripotent Stem Cell (iPSC) line as starting materials for manufacturing insulin-producing cells f
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks